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Abstract
The prion protein gene (Prnp) is highly influential in determining risk and susceptibility of sheep exposed to classical scrapie.
Sheep homozygous for alanine at codon 136 and arginine at codons 154 and 171 (ARR/ARR) of the Prnp gene are historically
considered to be highly resistant to classical scrapie, although they form a significant fraction of cases of atypical scrapie. To
date, experimental transmission of prions to ARR/ARR sheep has only been achieved with the BSE agent and mostly by the
intracerebral route. We summarise here the results of six separate studies, in which 95 sheep of the ARR/ARR genotype were
naturally exposed to (n = 18) or experimentally challenged with (n = 77) natural or experimental sources of classical scrapie
by the oral, intra-intestinal, subcutaneous or intracerebral routes and allowed to survive for periods of up to 94 months
post-infection. Only the intracerebral route resulted in disease and/or amplification of disease associated PrP (PrPd), and only
in two of 19 sheep that survived for longer than 36 months. Discriminatory immunohistochemistry and Western blot
confirmed the scrapie, non-BSE signature of PrPd in those two sheep. However, the neuropathological phenotype was
different from any other scrapie (classical or atypical) or BSE source previously reported in sheep of any Prnp genotype.
These studies confirm the widely held view that ARR/ARR sheep are highly resistant to classical scrapie infection, at least
within their commercial lifespan. Moreover, within the constraints of the present studies (only two infected sheep), these
results do not support the suggestion that atypical scrapie or BSE are generated by adaptation or mutation of classical
scrapie in sheep of resistant ARR/ARR genotype.
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Introduction
The transmissible spongiform encephalopathies (TSEs) are
characterised by the accumulation of abnormal forms of a host-
coded, cell membrane sialoglycoprotein called prion protein (PrP).
Scrapie, or classical scrapie, of sheep and goats is the archetypal
TSE and has been recognised as contagious outbreaks of disease
for several centuries. More recently, a novel, apparently non-
contagious or sporadic form of sheep TSE, originally called Nor
98 [1] and now more commonly referred to as atypical scrapie, has
been recognised in Europe and elsewhere.
The prion protein gene (Prnp) controls susceptibility to both
atypical and classical scrapie [2]. Sheep bearing alanine (A) or
valine (V) at codon 136 and glutamine (Q) at codon 171 of PrP are
susceptible to classical scrapie. In contrast, classical scrapie is
rarely reported in sheep homo- or hetero-zygous for the allele that
bears A at codon 136 and arginine (R) at codons 154 and 171. In
separate UK studies, sheep scrapie was not identified in aged
ARR/ARR or ARQ/ARR sheep in flocks or geographical regions
with endemic scrapie [3,4,5,6]. Other epidemiological studies also
show that scrapie is very rare in ARQ/ARR sheep and absent
from ARR/ARR sheep in the UK [7]. However, single cases of
natural scrapie infection in ARR/ARR sheep have been reported
from Germany, France [8] and possibly also Japan [9].
In contrast, atypical scrapie is relatively common in sheep that
are homozygous or heterozygous for ARR alleles but is rare in
genotypes considered highly susceptible to classical scrapie such as
the VRQ/VRQ genotype [10]. In addition, ARR/ARR sheep
succumb to cattle and sheep BSE infection following intracerebral
challenge, albeit with extended incubation periods relative to
homozygous ARQ sheep [11,12]. ARR/ARR sheep orally [13] or
intra-splenically [14] dosed with BSE may also sustain infection
though development of clinical disease was not achieved by these
routes.
Over the last two decades, we have performed several
experiments in which ARR/ARR sheep have been exposed to
natural scrapie or have been experimentally challenged by
different routes. The purpose of this report is to draw together
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the data from those studies and report the susceptibility of ARR/
ARR sheep to classical scrapie.
Materials and Methods
All studies, including experimental inoculations, care of animals
and euthanasia, were carried out in accordance with the UK
Animal (Scientific Procedures) Act 1986. Studies 1 and 3–6 were
performed at the Moredun Research Institute under licenses from
the UK Government Home Office number 60/2656 (renewed in
2005 with number 60/3646). Study 2 was carried out at the
Agricultural Development and Advisory Service facilities at High
Mowthorpe under project license number 70/5155. Animals were
monitored daily for the presence of neurological signs compatible
with scrapie and were euthanized once those signs reached a
standard, pre-determined end point (for details refer to [15]), when
showing signs of intercurrent disease unresponsive to treatment, or
for welfare reasons. In most cases, however, sheep were killed at
the scheduled termination of the different studies. In all cases,
euthanasia was performed by intravenous injection of barbiturate
overdose followed by exsanguination.
ARR/ARR sheep included in the different studies
Ninety-five ARR/ARR sheep were included in the following six
studies (Table 1 and Fig. 1):
Study 1 (Natural infection). In a closed flock of Suffolk
sheep, in which the average incidence of scrapie in ARQ/ARQ
sheep over a nine-year period was 84% [15], 18 ARR/ARR sheep
were allowed to survive for over 48 months (Table 1 and Fig. 1).
These ARR/ARR sheep were reared from birth in continuous
contact with scrapie infected individuals.
Study 2 (Oral infection with sheep scrapie). 26 ARR/
ARR Cheviot lambs were orally dosed at 2–3 weeks of age on five
consecutive days with 1 g of a brain pool homogenate (total dose
5 g) and were allowed to survive for 14 to 92 months post-infection
(mpi; Table 1 and Fig. 1). The brain pool homogenate (RBP1) was
made from whole brains taken from 17 scrapie affected sheep of
five different breeds and four Prnp genotypes (VRQ/VRQ, VRQ/
ARQ, ARQ/ARQ and VRQ/ARR), which originated from six
different farms. After challenge with the same 5 g oral dose, this
inoculum produced attack rates of 100% in VRQ homozygous
sheep [16,17] and of 64% in ARQ/ARR sheep [18]. A 1 g dose of
the same inoculum administered also by the oral route gave rise to
100% attack rates in VRQ/VRQ, VRQ/ARQ, VRQ/ARR and
ARQ/ARQ sheep [17,18].
Study 3 (Oral infection with experimental murine-
adapted scrapie). A total of 12 Suffolk or Cheviot ARR/
ARR sheep between the ages of 3–5 months were orally dosed
with 25 ml of a 20% suspension of brain from scrapie affected
mice (5 g tissue equivalent). Three sheep each were infected with
the murine adapted strains ME7, 22 A, 79 A, or 87 V, all of which
were originally derived from scrapie affected sheep, and killed
between 35–47 mpi (Table 1 and Fig. 1). The rationale for this
experiment and the results of challenging sheep of other genotypes
with the same murine strains were reported by Siso´ et al., [19].
Briefly, oral challenge of VRQ/VRQ sheep with the same 5 g
dose induced 100% attack rate with ME7, 50% with 22 A, 33%
with 79 A and 0% with 87 V. Attacks rates for the same dose and
route in ARQ/ARQ sheep (some of which were polymorphic at
codons 112, 141, or 168) were 86% with ME7, 83% with 22 A,
17% with 79 A and 0% with 87 V. All four murine scrapie strains
produced 100% attack rates in VRQ/VRQ and ARQ/ARQ
sheep when administered by a combined oral, subcutaneous and
intracerebral route.
Study 4 (Inoculation of intestinal loops with sheep
scrapie). Single isolated gut loops were created as described
previously [20] in six two month-old, scrapie-free ARR/ARR
Suffolk lambs. Loops were created to include the distal ileum with
its continuous Peyer’s patch and inoculated with 5 ml of a Suffolk
scrapie brain 20% homogenate (1 g tissue equivalent). Two sheep
were killed at 16 and 47 mpi because of intercurrent health
problems; the remaining 4 sheep were healthy when killed at the
end of the experiment at 70–72 mpi (Table 1). The inoculum was
sourced from scrapie confirmed clinical cases (pool of 10 ARQ/
ARQ sheep) from the naturally infected Suffolk flock described
above (study 1, see Fig. 1). In a different experiment, the same
inoculum was used to infect sheep of the VRQ/VRQ, VRQ/
ARQ and ARQ/ARQ genotypes either by the oral or subcuta-
neous routes with 100% attack rates in all cases [21].
Study 5 (Sub-cutaneous inoculation with sheep
scrapie). 13 New Zealand-derived ARR/ARR Suffolk lambs
were subcutaneously inoculated at 6 months of age with 1 ml of a
10% clarified homogenate of the same inoculum as used in study 4
(0.1 g tissue equivalent; Fig.1). The injection was done in the
drainage area of the right prefemoral lymph node, as described in
detail previously [22]. Seven ARR/ARR sheep were killed at
Table 1. Design of the different studies.
Study Exposure Source Dose Months post-infection or age at post-mortem examination Total
No. 0–12 13–24 25–36 37–48 49–60 61–72 73–84 85–96
1 Natural ARQ/ARQ n/a 9 5 1 3 18
2 Oral Sheep pool 5 3 3 3 3 3 11 26
3 Oral Murine strains 5 6 6 12
4 Intraintestinal ARQ/ARQ 1 1 1 4 6
5 Subcutaneous ARQ/ARQ 0.1 (+2*) 7 2 4* 13
6a Intracerebral ARQ/ARQ 0.1 2 4 4 10
6b Intracerebral VRQ/VRQ 0.1 1 1 8 10
Total 1 11 11 12 12 17 13 18 95
Age in months for naturally exposed sheep of study 1; months post-infection for all other studies. Sheep pool, pool of 17 scrapie brains (VRQ/VRQ= 6, VRQ/ARQ= 6,
ARQ/ARQ= 4, VRQ/ARR= 1).
Murine strains, sheep dosed with 22 A or 87 V killed at 35 mpi; sheep dosed with ME7 or 79 A killed at 47 mpi. Dose in grams: n/a, not applicable;
*, four sheep were boosted with 2 g of inoculum by the subcutaneous route (months post-inoculation correspond to those of original challenge).
doi:10.1371/journal.pone.0091026.t001
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22 mpi and two at 29 and 32 mpi; the remaining four were re-
challenged subcutaneously at 32 mpi with 10 ml (5 ml in each
flank) of a 20% dilution of the same inoculum (2 g tissue
equivalent) and killed 58 to 62 months after the second inoculation
(90 to 94 months after the original challenge; Table 1). The
inoculum used induced infection in 100% ARQ/ARQ Suffolk
sheep without threonine polymorphism at codon 112 when
injected by the same subcutaneous route [23].
Study 6 (Intracerebral inoculation with sheep
scrapie). In study 6a, 10 ARR/ARR Suffolk sheep were
intracerebrally challenged at four months of age with 0.5 ml of a
20% sheep scrapie brain homogenate (0.1 g tissue equivalent)
using a scrapie brain homogenate derived from an ARQ/ARQ
sheep from the naturally infected Suffolk flock described above
(Fig. 1). Two sheep were found dead at 39 and 43 mpi, another
four were culled at 61 to 72 mpi due to welfare issues and the
remaining four were killed at the end of the experiment (79 mpi;
Table 1). Two age-matched ARQ/ARQ sheep were also
inoculated (same inoculum, route and dose) and died at
,17 mpi with a pathological and biochemical scrapie phenotype
indistinguishable from that of the inoculum donor and other
ARQ/ARQ sheep in their flock.
In study 6b, 10 ARR/ARR Cheviot sheep were also
intracerebrally challenged at the same age and with the same
dose as the Suffolk sheep but with an inoculum derived from a
VRQ/VRQ Cheviot sheep that succumbed to confirmed scrapie
after oral infection with a brain pool homogenate of six natural
scrapie cases in sheep of the same breed and genotype all derived
from the same flock (Fig. 1; for details of this source see [21]). Two
sheep were found dead at 11 and 72 mpi, one was killed with
terminal neurological signs at 74 mpi and the remaining seven
were culled at the end of the experiment (79 mpi; Table 1). Two
age-matched VRQ/VRQ sheep were also inoculated (same
inoculum, route and dose) and died at ,5 mpi with a pathological
and biochemical scrapie phenotype that was indistinguishable
from that of the donor sheep.
Laboratory examinations
From each of the above studies, a detailed necropsy was
performed and samples of lymphoid tissues, digestive tract, brain
and spinal cord, peripheral and autonomic nervous system tissues,
striated muscles and other organs were taken for immunohisto-
chemical (IHC) examinations, as detailed in table 2. Tissues were
processed to paraffin wax and stained with haematoxylin and
eosin (brain only) or subjected to IHC labelling for disease
associated PrP (PrPd) using R145 monoclonal antibody (binding to
ovine PrP amino acid [aa] sequence 222–226 [24]) as described
previously [11]. Two additional PrP antibodies, F99 (aa sequence
220–225 [25]) and 3F10 (aa sequence 137–151 [26]) were used in
serial sections to help confirming low levels of PrPd accumulation
found with R145. In addition, 2A11 (aa sequence 163–171 [27],
and SAF 84 (aa sequence 166–172 [28]), monoclonal antibodies
that do not recognize R at codon 171 were also used on tissue
sections where positive PrPd labelling was detected with R145.
Western blotting (WB) was carried out in samples of medulla
oblongata and/or cerebellum of all sheep using P4 (aa sequence
93–99 [29]) and SAF84 PrP antibodies as described previously
[21] to detect protease resistant PrP (PrPres). In addition, samples
of five different brain areas from the only sheep that developed
clinical scrapie were examined with L42 (aa sequence 148–153
[28]) and F99 PrP monoclonal antibodies.
The Bio- Rad TeSeE ELISA is the screening test used in the
current statutory UK small ruminant TSE surveillance pro-
gramme, and was used to test cerebellum samples from all 20
intracerebrally challenged ARR/ARR sheep and the four controls
of that experiment (study 6).
Figure 1. Design of the different studies with reference to the source of the inocula used. In green, inocula used; in blue, source of the
inocula; in black use of the inocula for the six different studies on ARR/ARR sheep; in red, use of the same inocula to challenge sheep of susceptible
genotypes.
doi:10.1371/journal.pone.0091026.g001
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Results
Attack rates
None of the 64 sheep surviving for less than 72 months after
scrapie challenge showed any post-mortem indication of PrPd
accumulation. These included 14 naturally exposed sheep, 27
orally dosed (including the 12 dosed with murine scrapie), all six
receiving intra-intestinal inoculation, nine injected subcutaneously
and six infected intracerebrally. Among the remaining 33 sheep,
which were aged or survived for 72 or more mpi, none of the four
naturally exposed, the 11 orally dosed with sheep scrapie or the
four inoculated subcutaneously were positive for PrPd/PrPres,
either by IHC or WB, in any of the tissues examined. Of the 14
sheep challenged by the intracerebral route only two, one Cheviot
and one Suffolk sheep, showed PrPd accumulation, as described
below. In summary, these results indicate attack rates of 0% in
sheep naturally exposed or experimentally infected by routes other
than the intracerebral, regardless of their survival time. For
intracerebrally challenged sheep, attack rates would vary between
10% (2/20), if all inoculated sheep are considered, and 14.3% (2/
14), if only those coeval or older than the first indication of
infection (72 mpi) are accounted for.
PrPd positive ARR/ARR Suffolk sheep
One neurologically unremarkable ARR/ARR Suffolk sheep
intracerebrally challenged with ARQ/ARQ Suffolk scrapie was
culled at 72 mpi because of persistent lameness and problems
related to its hooves. On histological examination of the brain this
sheep showed neuropil vacuolation in the thalamus. Immunohis-
tochemistry confirmed PrPd accumulation in the thalamus (Fig. 2a),
the midbrain, the parietal cerebral cortex and the obex. PrPd was
almost exclusively present in the form of particulate accumulation
within the neuropil. In the obex, sparse particulate deposits of PrPd
Table 2. Details of tissues examined routinely by IHC in ARR/
ARR sheep of the different studies.
Tissue Study number
1 2 3 4 5 6
Lymphoid tissues
Pharyngeal tonsil X
Palatine tonsil X X X X X X
Nictitating membrane X X X
Medial retropharyngeal LN X X X X X
Lateral retropharyngeal LN X
Submandibular LN X X X
Parotid LN X
Prescapular LN X X X
Tracheobronchial LN X
Mediastinal LN X
Mesenteric LN X X X X
Ileocecal LN X
Inguinal LN X X
Popliteal LN X X








Jejunum X X X
Ileum X X X X X
Caecum X
Colon X X
Rectum X X X X
Central nervous system X X X X
Frontal cortex X X X X
Corpus striatum X X X X X
Thalamus/hypothalamus X
Hippocampus X X X X
Midbrain X X X X
Cerebellum X X X X X
Medulla oblongata X X X X
Obex X X X X X X
Cervical spinal cord X X X
Thoracic spinal cord X X X
Lumbar spinal cord X X X
Retina X X
Peripheral nervous system
Trigeminal G X X X
Nodose G X X X
Cranial cervical G X
Stellate G X X
Sympathetic chain X X X
Table 2. Cont.
Tissue Study number
1 2 3 4 5 6
Vago-sympathetic trunk X
Vagus nerve X X X
Cranial mesenteric G X X X
Radial nerve X
Sciatic nerve X X
Muscles and other organs
Semitendinous muscle X X
Intercostal muscle X X
Occular muscles X X
Tongue X




Adrenal gland X X X
LN, lymph node; G, ganglion.
Most digestive tract tissues provided opportunity to examine both nervous and
lymphoid components.
Tissues examined in each study (for description of each study refer to text) are
marked with an X.
doi:10.1371/journal.pone.0091026.t002
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were present in the spinal tract of the trigeminal nerve but not in
the dorsal motor nucleus of the vagus nerve (Fig. 2b). Immuno-
reactivity to R145 antibody was confirmed by positive immuno-
labelling with F99 and 3F10 but no PrPd was detected with either
SAF 84 or 2A11, confirming the ARR variant of the protein.
PrPres was not detected by WB or ELISA done on brain samples
and all other tissues examined by IHC were also negative.
PrPd positive ARR/ARR Cheviot sheep
One ARR/ARR Cheviot sheep intracerebrally challenged with
VRQ/VRQ Cheviot scrapie collapsed after a short clinical course
of 3 weeks, in which the animal displayed vague neurological signs,
and was killed at 75 mpi. The brain showed severe vacuolation
throughout all grey matter regions and PrPd was also present
throughout all neuroanatomical areas of the brain and spinal cord.
A wide range of PrPd types [30] were present including types
consistent with intra-neuronal and intra-glial and several extra-
cellular types. Most of the latter were in the form of coarse or fine
diffuse particulate PrPd in the grey matter neuropil, while glial
associated perivascular aggregates were infrequent. In the
thalamus and cerebral cortex, distinctive, multifocal, intensely-
labelled mini plaque-like deposits and marked intra-astrocytic PrPd
accumulations were observed (Fig. 2c,d). Labelling was absent
when R145 positive areas were incubated with antibodies 2A11 or
SAF 84. Neither the pattern of vacuolation nor the pattern and
distribution of PrPd accumulation was consistent with that of the
VRQ/VRQ Cheviot donor or the two positive control sheep.
These showed less intense and less widespread vacuolation
(Fig. 3a,b), predominant stellate type of PrPd and absence of mini
plaques, although the intra-glial, intra-neuronal and diffuse
particulate PrPd types were in common with ARR/ARR sheep
(Fig. 3c,d).
PrPd accumulation was not detected in the lymphoid system,
digestive tract or in most of the peripheral nervous system and
other tissues examined. In the retina, diffuse PrPd labelling was
found in the outer plexiform layer and coarse particulate deposits
in the inner plexiform layer and in the soma of retinal ganglion
cells (Fig 4a). Low levels of PrPd accumulation were found in the
trigeminal ganglion’s satellite cells (Fig 4b) and in intrafusal fibres
of the infra-orbital muscles (Fig 4c). In trigeminal ganglion peri-
axonal PrPd accumulation was detected in myelinated axons.
Incubation of serial sections with F99 (Fig 4d) and 3F10 confirmed
the specificity of labelling in these tissues.
Western blotting of brain samples incubated with P4, L42 or
F99 (Fig. 5a) confirmed the presence of PrPres in the obex, frontal
cortex, thalamus, midbrain and cerebellum. The highest signal
was detected in cerebellum. In almost all brain areas tested the
strongest PrPres signal was obtained from the monoglycosylated
fraction, which contrasted with the strongest signal of the
diglycosylated fraction in the VRQ/VRQ donor and control
recipients (Figs. 5a and 5b). The mobility of the unglycosylated
fraction corresponded to a molecular weight of ,20 to 21 kDa,
Figure 2. PrPd accumulation in CNS tissues of clinically affected and pre-clinical ARR/ARR sheep. a) Cerebral cortex of an ARR/ARR
Cheviot sheep challenged with a VRQ/VRQ scrapie source showing marked diffuse particulate PrPd accumulation in grey matter with multifocal mini–
plaque like accumulations. Bar = 500 mm. IHC with R145 PrP antibody and haematoxylin counterstaining. b) Detail of the cerebral cortex of the ARR/
ARR scrapie affected Cheviot sheep showing diffuse, marked intra-astrocytic PrPd and multifocal intense mini-plaque–like PrPd accumulations. Bar
= 50 mm. IHC with R145 PrP antibody and haematoxylin counterstaining. c) Pre-clinical ARR/ARR Suffolk sheep challenged with ARQ/ARQ scrapie
sources. Note absence of detectable PrPd accumulation in the dorsal motor nucleus of the vagal nerve. Bar = 200 mm. IHC with R145 PrP antibody
and haematoxylin counterstaining. d) Pre-clinical ARR/ARR Suffolk sheep showing diffuse grey matter PrPd accumulation in the thalamus. Bar 200 mm.
IHC with R145 PrP antibody and haematoxylin counterstaining.
doi:10.1371/journal.pone.0091026.g002
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similar to that of the VRQ/VRQ and ARQ/ARQ controls and
consistent with classical scrapie. When the same brain samples
were incubated with SAF84 (Fig. 5a), no signal or only trace
signals were obtained for any of the bands. These observations are
in agreement with the 2A11 and SAF84 IHC results, and indicate
that PrPres was of the ARR variant.
The Bio-Rad TeSeE ELISA gave positive test values in brain
samples from VRQ/VRQ and ARQ/ARQ positive scrapie
controls and from the clinically affected ARR/ARR Cheviot
sheep.
Discussion
In agreement with previously published studies, the above
experiments show that ARR/ARR sheep are extremely resistant
to classical scrapie when naturally exposed to a highly contam-
inated environment or when infected by experimental protocols
that approximate natural exposure. However, experimental intra-
cerebral challenge shows that it is possible to induce disease in
sheep of this genotype, albeit with low attack rates and incubation
periods that are years longer than those in sheep of susceptible
genotypes. Therefore, these data provide proof of principle that
ARR/ARR sheep are susceptible to UK classical sheep scrapie
sources albeit only by a highly artificial and efficient route of
challenge.
The experimental gut loop protocol circumvents transit of orally
dosed infectivity through the upper part of the alimentary system,
avoiding enzymatic degradation of PrPd. It thus maximises the
opportunity of transport of infectivity across the intestinal barrier
to permit amplification of infectivity in gut associated lymphoid
tissues of susceptible sheep [20]. Despite this and a relatively large
dose, this route did not result in generalised or even localised
amplification of PrPd in ARR/ARR sheep. Equally, oral and
subcutaneous infection did not result in transmission of infection.
Failure to induce classical scrapie using these routes of inoculation
is more relevant to natural disease than the intra-cerebral route,
particularly when considering that the volumes of inocula used
were in excess of those likely to be found under environmental
conditions of even the highest infectivity pressure. The lack of
transmission in these experiments is consistent with the absence of
infection in ARR/ARR sheep exposed for prolonged periods to a
highly contaminated environment (the ‘‘natural infection’’ group)
and with many other epidemiological studies of natural scrapie in
the UK [3,4,5,6,7] and elsewhere [31] which do not report
classical scrapie in ARR/ARR sheep.
However, single cases of classical scrapie have been reported in
ARR/ARR sheep from Japan [9], Germany and France [8], and
in all instances by the detection of PrPres in Western blot analyses
of brain samples. The Japanese case, a Suffolk sheep, appeared to
be clinically affected but no data are available about the clinical or
pathological phenotype of the disease. The German case, a black-
Figure 3. PrPd labelling and vacuolation in the cerebellar cortex of VRQ/VRQ and ARR/ARR sheep. a) VRQ/VRQ sheep showing diffuse
particulate and stellate types of PrPd accumulation in the cerebellar molecular layer. Vacuolation is relatively subtle. Bar 200 mm. IHC with R145 PrP
antibody and haematoxylin counterstaining. b) VRQ/VRQ sheep showing detail of the stellate type of PrPd accumulation centred on glial cell nuclei in
the molecular layer of the cerebellum. Bar 50 mm. IHC with R145 PrP antibody and haematoxylin counterstaining. c) ARR/ARR sheep showing diffuse
particulate but not stellate PrPd accumulation in both molecular and internal granule cell layers and prominent intra-glial types of PrPd accumulation
in the cerebellar molecular layer. Vacuolation is abundant. Bar 200 mm. IHC with R145 PrP antibody and haematoxylin counterstaining. d) ARR/ARR
sheep showing detail of the intensity of particulate type of PrPd accumulation and intense granular PrPd accumulation associated with glial cell nuclei
(intra-microglial type) in the cerebellar molecular layer. Bar 100 mm. IHC with R145 PrP antibody and haematoxylin counterstaining.
doi:10.1371/journal.pone.0091026.g003
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headed German mutton sheep, was apparently healthy and the
French case, a 5 year-old sheep, showed neurological signs of
histopathologically confirmed listeriosis. Detailed data on clinico-
pathological phenotypes are not available for either case, although
the French case was successfully transmitted to Tg338 mice [8].
These reports suggest that cases of classical scrapie may occur
naturally in ARR/ARR sheep, although all epidemiological and
experimental evidence indicate that such occurrences would be
sporadic or exceptional. However, more frequent detection of such
cases may be hampered by current sampling strategies which focus
on the hind brain, as shown by the failure of statutory ELISA
testing to detect the single pre-clinically affected intra-cerebrally
challenged Suffolk sheep in the present study.
ARR/ARR sheep also appear to be much more resistant to
infection with classical scrapie than with experimental sheep BSE.
Thus, ARR/ARR sheep intra-cerebrally challenged with 0.5 mg
tissue equivalent of sheep BSE (i.e., allowing for potential
differences in infectious titre, a 500 times smaller dose than in
the scrapie experiment reported here) developed clinical disease
with a 100% attack rate and a survival time of 4965 months [12].
Similarly, ARR/ARR sheep intra-cerebrally challenged with
cattle BSE showed figures of 56% attack rate and 49613 months
survival time (Houston et al., unpublished observations). More-
over, susceptibility of ARR/ARR sheep to sheep BSE by the oral
route [13] and to cattle BSE by the intra-splenic route [14] has
been documented, while oral, intra-intestinal and sub-cutaneous
challenge with sheep scrapie and murine adapted sheep scrapie
failed to transmit infection, at least as judged by PrPd or PrPres
detection. The difference in pathogenicity of BSE and scrapie
agents for ARR/ARR sheep does not appear to be a property of
the agents per se as this difference in pathogenicity is not observed
in sheep of other genotypes. For example, oral infection of ARQ/
ARQ sheep (without polymorphisms at codons 112 or 141) with
ARQ/ARQ sheep scrapie results in complete attack rates and
short survival times of 2362 months [21], while sheep of the same
genotype inoculated by the same route and with the same 5 g dose
of ARQ/ARQ sheep BSE also showed a 100% attack rate and
survival times of 2362 months (first passage) or 2562 months
(second passage) [32]. Similarly, oral infection of VRQ/VRQ
sheep with ARQ/ARQ sheep scrapie produces a 100% attack rate
with survival times of 4767 months [21] and infection of sheep of
the same genotype with cattle BSE by the same route and dose
also results in complete attack rate figures and survival times of
,59 months (Jeffrey et al., unpublished observations). It is worth
pointing out that despite the studies reported here using a variety
of natural and experimental scrapie sources, all of which proved to
be infectious for sheep of susceptible Prnp genotypes
[15,16,17,18,19,21,23], the number of such sources was limited.
We cannot therefore rule out the possibility that other sources or
strains of classical scrapie could result in higher attack rates or
different disease phenotypes in ARR/ARR sheep, as is found with
the BSE agent.
Figure 4. Additional tissues of ARR/ARR clinically affected Cheviot sheep showing PrPd accumulation. a) Retina showing diffuse PrPd
accumulation in outer plexiform layer and granular accumulations in inner plexiform layer and retinal ganglion cells. Bar = 50 mm. IHC with R145 PrP
antibody and haematoxylin counterstaining. b) Trigeminal ganglion showing granular PrPd accumulation in satellite cells Bar = 50 mm. IHC with R145
PrP antibody and haematoxylin counterstaining. c) Muscle spindle from ocular muscle showing weak granular PrPd accumulation in intrafusal muscle
fibres (arrows). Bar = 50 mm. IHC with R145 PrP antibody and haematoxylin counterstaining. d) The same muscle spindle as in c) labelled with anti- PrP
antibody F99. The same intrafusal muscle fibres as with R145 are labelled (arrows). Bar = 50 mm. IHC with F99 PrP antibody and haematoxylin
counterstaining.
doi:10.1371/journal.pone.0091026.g004
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Although the pathological and biochemical features of the single
clinical scrapie case in an ARR/ARR genotype in our studies was
consistent with classical rather than atypical scrapie or BSE, the
disease phenotype was dissimilar to the VRQ/VRQ case that
provided the inoculum and to the two VRQ/VRQ positive
control sheep challenged with the same inoculum. The patholog-
ical phenotype of this single ARR/ARR scrapie case has little
resemblance to any other classical scrapie source the authors have
examined in any sheep breed or Prnp genotype. This suggests that
although some sort of modification occurs on passage of classical
scrapie into ARR/ARR sheep, such change does not result in the
emergence of atypical scrapie or BSE and also reinforces the
notion that the interaction between the infecting source and the
Prnp genotype of the host has significant impact on the
susceptibility to scrapie and on the disease phenotype [21].
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Figure 5. Western blotting of different brain areas of ARR/ARR clinically affected Cheviot sheep. a) Western blots of brain tissue with 4
different PrP antibodiesImmunoblots of frontal cortex (FC) thalamus (TH) midbrain (MB) cerebellum (CB) and medulla at the level of the obex (MO)
each showed significant accumulation of PrPres with antibodies P4, L42, and F99. With each of these antibodies the cerebellum showed the greatest
concentration of PrPres. Compared with ARQ/ARQ and VRQ/VRQ scrapie positive control obex samples, the mono-glycosylated band predominates in
most of the ARR/ARR samples. The unglycosylated band from all ARR/ARR and positive control samples has a molecular weight of,20 to 21 kDa. No
labelling or only trace labelling was found when the antibody SAF84 was used. Mol mkr: molecular weight marker (Note: the molecular weight
marker produced a very faint signal with L42. To position the weight reference values the blot was digitally overexposed but it is the original, non-
saturated blot that is reproduced). b) Graph showing the proportion of di-glycosylated and mono-glycosylated PrPres for brain from the clinically
affected ARR/ARR sheep in comparison with ARQ/ARQ and VRQ/VRQ controls. For each of the brain sites the mono-glycosylated fraction of PrPres was
present in a relatively greater amount than the di-glycosylated fraction when labelled with either P4 or L42 antibodies. In contrast both VRQ/VRQ
control and ARQ/ARQ positive controls had a relatively greater amount of di-glycosylated PrPres. Values for P4 antibody are shown in blue and for L42
in red; frontal cortex, diamonds; thalamus, squares; midbrain, triangles; cerebellum, circles; obex, pentagons; the Suffolk sheep ARQ/ARQ positive
control (obex) is outlined in orange and the Cheviot sheep VRQ/VRQ positive control (obex) is outlined in green.
doi:10.1371/journal.pone.0091026.g005
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